Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito, the mosquitoes that alos spread dengue and chikungunya viruses.

Phase I Human Trial of Zika Vaccine Approved

"We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers," said Dr. J. Joseph Kim, Inovio Pharmaceuticals, Inc.'s president and CEO. "We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year."

Inovio Pharmaceuticals, Inc. (Plymouth Meeting, Pa., and San Diego, Calif.) and GeneOne Life Science, Inc. (Seoul, South Korea) have received approval to initiate a phase I human trial to evaluate Inovio's Zika DNA vaccine to prevent infection from the virus, the companies announced June 20. In preclinical testing, the synthetic vaccine "induced robust antibody and T cell responses in small and large animal models, demonstrating the product's potential to prevent infection from this harmful pathogen in humans," they reported.

Their phase I, open-label, dose-ranging study with 40 healthy subjects will evaluate vaccine's safety, tolerability, and immunogenicity.

"We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers. As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus; the incidences of viral infection and medical conditions caused by the virus are expanding, not contracting. We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year," said Dr. J. Joseph Kim, Inovio's president and CEO.

"It is an honor for our company to help usher this Zika vaccine through the clinical and regulatory process. We look forward to conducting this trial with the goal of achieving products to combat this dreaded virus," agreed Young K. Park, GeneOne's president and CEO.

The two companies are developing the Zika vaccine, GLS-5700, with academic collaborators from the United States and Canada with whom they previously collaborated to advance Inovio's Ebola and MERS vaccines into clinical development.

Currently there is no vaccine or therapy for the Zika virus.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Comply with OSHA’s Electronic Recordkeeping Requirements

    Collect relevant incident data and generate accurate OSHA 300, 300A, and 301 regulatory reports, including 300A CSV files for easy electronic submission to OSHA.

  • Complete Online Safety Training Courses

    Deliver state-of-the art, online safety training courses to your organization with IndustrySafe Training Management Software. Generate reports to track training compliance and automatically notify learners of upcoming or overdue classes.

  • Easy to Use Safety Inspection App

    Conduct inspections on the go with IndustrySafe’s mobile app. Complete safety audits at job sites and remote locations—with or without web access.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Industry Safe
comments powered by Disqus